Move over, oncology: Obesity, diabetes meds will take over 2030's top drug rankings, Evaluate forecasts
Fierce Pharma
JULY 10, 2024
It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. | Novo Nordisk's Ozempic is slated to take over No.1, while Merck's Keytruda falls to No.9 on Evaluate's predicted rankings of top drugs by 2030 sales.
Let's personalize your content